论文部分内容阅读
目的 评价三联药物方案治疗慢性自发性荨麻疹的临床疗效及安全性.方法 将2014年4月-2016年4月本科诊治的130例慢性自发性荨麻疹患者采用随机数字表法分为两组,各65例.对照组予地氯雷他定联合左西替利嗪,治疗组予地氯雷他定联合左西替利嗪及白芍总苷,疗程均为8周.结果 治疗组近期疗效显著优于对照组,治疗组患者风团持续时间显著短于对照组,治疗组患者治疗后UAS7评分显著低于对照组和其治疗前UAS7评分,治疗组患者复发率显著低于对照组,以上差异均有统计学意义(均P ＜0.05).但是两组患者不良反应发生率差异无统计学意义(P＞0.05).结论 三联药物治疗慢性自发性荨麻疹可有效缓解患者的临床症状和体征,降低远期复发风险,且安全性好.“,”Objective To investigate the clinical effects and safety of triple combination scheme in the treatment of patients with chronic idiopathic urticaria.Methods One hurdred and thirty patients with chronic idiopathic urticaria were chosen in the period from April 2014 to April 2016 in Dermatology Department of Central Hospital of Dazhou City and randomly divided into both group including control group (65 patients) with desloratadine + cetirizine and observation group (65 patients) with desloratadine + cetirizine + total glucosides of paeony for 8 weeks.Results The clinical efficacy for short-term of observation group were significantly better than control group.The pruritus lasting time of observation group were significantly shorter than control group.The UAS7 scores after treatment of observation group were significantly lower than control group and before treatment of observation group.The recurrence rate with follow-up of observation group were significantly lower than control group.There were statistically significant difference in above indexes between 2 groups (all P ＜ 0.05).But there was no statistically significant difference in the adverse effects incidence between 2 groups (P ＞ 0.05).Conclusion Triple combination scheme in the treatment of patients with chronic idiopathic urticaria can efficiently relieve clinical symptoms and signs,reduce the recurrence rate for long-term and not cause to serious adverse reactions.